PulseAugur
EN
LIVE 20:30:42
中文(ZH) 中关村:利多卡因丁卡因乳膏收到《药物临床试验批准通知书》

Zhongguancun subsidiary gets drug trial approval; *ST Yabo wins energy storage bid; OpenAI halts GPT-6 push

A subsidiary of Zhongguancun has received approval for clinical trials of a lidocaine-tetracaine cream for topical anesthesia before skin surgery. Separately, a company called *ST Yabo has won a bid for a 50MW/100MWh frequency regulation energy storage power station project for 99.8 million yuan. The cluster also mentions trends for WAIC 2026 and a report that OpenAI has urgently halted the push for GPT-6. AI

IMPACT Reports of OpenAI halting GPT-6 push suggest potential shifts in AI development timelines or strategy.

RANK_REASON The cluster contains multiple unrelated news items, including a drug trial approval, an energy storage project bid, and a speculative report about OpenAI's GPT-6, none of which constitute a primary frontier release or significant industry event.

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Zhongguancun subsidiary gets drug trial approval; *ST Yabo wins energy storage bid; OpenAI halts GPT-6 push

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Zhongguancun: Lidocaine-Prilocaine Cream Receives 'Drug Clinical Trial Approval Notice'

    36氪获悉,中关村公告,下属公司北京华素于近日收到国家药品监督管理局核准签发的利多卡因丁卡因乳膏《药物临床试验批准通知书》,同意本品开展用于成人皮肤手术前对完整皮肤的局部麻醉的临床试验。